Description du projet
Un développement innovant pour un traitement individualisé de la tuberculose
La tuberculose (TB) est causée par Mycobacterium tuberculosis et constitue l’une des principales maladies infectieuses dans le monde. Les méthodes conventionnelles de diagnostic et de test de sensibilité aux médicaments ne sont pas assez efficaces pour contrôler la maladie, et tous les patients tuberculeux suivent la même durée de traitement, ce qui entraîne souvent des effets indésirables, une adhésion peu soutenue aux directives de traitement et de piètres résultats. Financé par le programme Actions Marie Skłodowska-Curie, le projet INNOVA4TB entend introduire des technologies et des approches innovantes pour l’évaluation du risque individuel de progression de la tuberculose, le diagnostic rapide et le test de prédisposition aux médicaments de la souche. Ces approches permettront d’élaborer des thérapies sur mesure assorties d’une durée de traitement antimicrobien individualisée.
Objectif
The objective of INNOVA4TB is to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of tuberculosis (TB). The consortium is constituted by 12 institutions from 8 countries that combine complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions allow the participants to progress in their career perspectives.
TB is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A transition from programmatic to personalized management of TB is needed. Our proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for TB development, to rapidly diagnose active TB, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. This is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.
Champ scientifique
Programme(s)
Régime de financement
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Coordinateur
08916 Badalona Barcelona
Espagne